TerminatedPhase 1NCT00368329

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

Studying Adenocarcinoma of the cervix uteri

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stanford University
Principal Investigator
Daniel T Chang
Stanford University
Intervention
Capecitabine (Xeloda)(drug)
Enrollment
4 enrolled
Eligibility
18 years · All sexes
Timeline
20062009

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00368329 on ClinicalTrials.gov

Other trials for Adenocarcinoma of the cervix uteri

Additional recruiting or active studies for the same condition.

See all trials for Adenocarcinoma of the cervix uteri

← Back to all trials